BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Clinical Outcome
6 results:

  • 1. Lymphocytes, Interleukin 6 and D-dimer Cannot Predict clinical outcome in Coronavirus cancer Patients: LyNC1.20 Study.
    Vanni G; Materazzo M; Dauri M; Farinaccio A; Buonomo C; Portarena I; Pellicciaro M; Legramante JM; Rizza S; Chiaramonte C; Bellia A; Grande M; Potenza S; Sbordone FP; Perrone MA; Grimaldi F; Chiocchi M; Buonomo OC
    Anticancer Res; 2021 Jan; 41(1):307-316. PubMed ID: 33419825
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
    Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
    Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
    [No Abstract]    [Full Text] [Related]  

  • 3. Molecular Characterization and clinical Relevance of Metabolic Expression Subtypes in Human cancers.
    Peng X; Chen Z; Farshidfar F; Xu X; Lorenzi PL; Wang Y; Cheng F; Tan L; Mojumdar K; Du D; Ge Z; Li J; Thomas GV; Birsoy K; Liu L; Zhang H; Zhao Z; Marchand C; Weinstein JN; ; Bathe OF; Liang H
    Cell Rep; 2018 Apr; 23(1):255-269.e4. PubMed ID: 29617665
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
    Marouf C; Göhler S; Filho MI; Hajji O; Hemminki K; Nadifi S; Försti A
    BMC Cancer; 2016 Feb; 16():165. PubMed ID: 26920143
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Expression of runx1 correlates with poor patient prognosis in triple negative breast cancer.
    Ferrari N; Mohammed ZM; Nixon C; Mason SM; Mallon E; McMillan DC; Morris JS; Cameron ER; Edwards J; Blyth K
    PLoS One; 2014; 9(6):e100759. PubMed ID: 24967588
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism.
    Ibrahim SA; Yip GW; Stock C; Pan JW; Neubauer C; Poeter M; Pupjalis D; Koo CY; Kelsch R; Schüle R; Rescher U; Kiesel L; Götte M
    Int J Cancer; 2012 Sep; 131(6):E884-96. PubMed ID: 22573479
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.